Global Market Presence Biocodex operates in over 100 countries through a combination of wholly owned subsidiaries and distributors, providing ample opportunities to introduce new microbiota or probiotic products across diverse markets and healthcare systems.

Focus on Microbiota With a strong emphasis on microbiota care and recent partnerships with biotech leaders like My Health and MaaT Pharma, there is significant potential to expand product offerings and licensing agreements in microbiota-based therapies.

Innovative Acquisitions The recent acquisition of assets from THX Pharma and the purchase of supplement brands like Hilma indicate openness to expanding the product portfolio through strategic acquisitions, creating opportunities for complementary products and sales channels.

Financial Strength Generating over 500 million euros in revenue with a large international footprint and a substantial workforce suggests robust financial backing, enabling investment in new product development, marketing initiatives, and global expansion strategies.

Industry Collaborations Partnerships with research entities and biotech brands, along with the launch of the Biocodex Microbiota Institute, highlight opportunities to collaborate on clinical studies, research projects, and innovative microbiota solutions to meet rising healthcare demands.